{"id":619232,"date":"2022-09-30T13:48:01","date_gmt":"2022-09-30T13:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=619232"},"modified":"2022-09-30T13:48:01","modified_gmt":"2022-09-30T13:48:01","slug":"retinal-vein-occlusion-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-taiwan-liposome-company-aerie-pharmaceuticals-graybug-vision-outlook-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/retinal-vein-occlusion-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-taiwan-liposome-company-aerie-pharmaceuticals-graybug-vision-outlook-therapeutics_619232.html","title":{"rendered":"Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies &#8211; Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1664540097.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1664540097.jpeg\" alt=\"Retinal Vein Occlusion Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Retinal Vein Occlusion market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Vein Occlusion pipeline products will significantly revolutionize the Retinal Vein Occlusion market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong> &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Retinal Vein Occlusion Market Insights<\/a>, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Retinal Vein Occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Retinal Vein Occlusion Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Retinal vein occlusion (RVO), second most common retinal vascular disorder after diabetic retinopathy, is an obstruction of the retinal venous system by thrombus formation and may involve the central, hemi-central, or branch retinal vein. The most common etiological factor is compression by adjacent atherosclerotic retinal arteries. Other possible causes are external compression or disease of the vein wall, e.g., vasculitis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Retinal Vein Occlusion Market Report: &nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Retinal Vein Occlusion market size was valued at <strong>USD 2,378.1 Million<\/strong> in the year 2021 and is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)&nbsp;<\/strong><\/li>\n<li>In the year 2021, the total prevalent cases of Retinal Vein Occlusion were approximately <strong>2,708,118 cases<\/strong> in the 7MM, which are expected to increase by 2032&nbsp;<\/li>\n<li>Among EU-5 countries, the highest number of prevalent cases of Retinal Vein Occlusion were in Germany <strong>(approximately 225,397 cases)<\/strong> in the year 2021, which are expected to increase by 2032&nbsp;<\/li>\n<li>In 2021, the total diagnosed prevalent cases of Retinal Vein Occlusion in the 7MM were approximately <strong>1,518,208 cases<\/strong>, which are estimated to increase by 2032&nbsp;<\/li>\n<li><strong>Key Retinal Vein Occlusion Companies:<\/strong> Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others&nbsp;<\/li>\n<li><strong>Key Retinal Vein Occlusion Therapies:<\/strong> TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others&nbsp;<\/li>\n<li>The Retinal Vein Occlusion epidemiology based on type-specific distribution analyzed that the type-specific distribution of Retinal Vein Occlusion suggests a higher prevalence of BRVO than CRVO&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinal-vein-occlusion-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Retinal Vein Occlusion Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Retinal Vein Occlusion Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Retinal Vein Occlusion market report covers a descriptive overview and comprehensive insight of the Retinal Vein Occlusion Epidemiology and Retinal Vein Occlusion market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Retinal Vein Occlusion market report provides insights on the current and emerging therapies.<\/li>\n<li>Retinal Vein Occlusion market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Retinal Vein Occlusion market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Retinal Vein Occlusion market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Retinal Vein Occlusion market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinal-vein-occlusion-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Retinal Vein Occlusion market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Retinal Vein Occlusion Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Retinal Vein Occlusion market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Retinal Vein Occlusion<\/li>\n<li>Prevalent Cases of Retinal Vein Occlusion by severity<\/li>\n<li>Gender-specific Prevalence of Retinal Vein Occlusion<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Retinal Vein Occlusion&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Retinal Vein Occlusion Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Retinal Vein Occlusion market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as <strong>AR-1105, GB-102, ONS-5010,<\/strong> and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Retinal Vein Occlusion epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinal-vein-occlusion-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Retinal Vein Occlusion Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Retinal Vein Occlusion Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rich Retinal Vein Occlusion pipeline&nbsp;<\/li>\n<li>Advancement in drug Retinal Vein Occlusion therapies<\/li>\n<li>Increase in knowledge and awareness&nbsp;<\/li>\n<li>Increasing prevalence of Retinal Vein Occlusion<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Retinal Vein Occlusion Therapies and Key Companies<\/p>\n<ul style=\"text-align: justify;\">\n<li>TLC399: Taiwan Liposome Company<\/li>\n<li>AR-1105: Aerie Pharmaceuticals<\/li>\n<li>GB-102: Graybug Vision<\/li>\n<li>ONS-5010 (Lytenava): Outlook Therapeutics<\/li>\n<li>KSI-301: Kodiak Sciences<\/li>\n<li>Vabysmo (faricimab): Roche\/ Chugai Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Retinal Vein Occlusion Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Retinal Vein Occlusion Companies:<\/strong> Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche, Chugai Pharmaceuticals, and others<\/li>\n<li><strong>Key Retinal Vein Occlusion Therapies:<\/strong> TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), and others<\/li>\n<li><strong>Retinal Vein Occlusion Therapeutic Assessment:<\/strong> Retinal Vein Occlusion current marketed and Retinal Vein Occlusion emerging therapies<\/li>\n<li><strong>Retinal Vein Occlusion Market Dynamics:&nbsp;<\/strong> Retinal Vein Occlusion market drivers and Retinal Vein Occlusion market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Retinal Vein Occlusion Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Retinal Vein Occlusion Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Retinal Vein Occlusion Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cost Consciousness&nbsp;<\/li>\n<li>Risk and complications&nbsp;<\/li>\n<li>Lack of focus on for visual restoration&nbsp;<\/li>\n<li>Failure of investigational drugs&nbsp;<\/li>\n<li>Invasion of biosimilar in future<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Retinal Vein Occlusion Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Retinal Vein Occlusion<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Retinal Vein Occlusion<\/p>\n<p style=\"text-align: justify;\">4. Retinal Vein Occlusion Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Retinal Vein Occlusion Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Retinal Vein Occlusion Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Retinal Vein Occlusion Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Retinal Vein Occlusion&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Retinal Vein Occlusion Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Retinal Vein Occlusion Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Retinal Vein Occlusion Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Retinal Vein Occlusion Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Retinal Vein Occlusion Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Retinal Vein Occlusion Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Retinal Vein Occlusion Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Retinal Vein Occlusion Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Retinal Vein Occlusion Appendix<\/p>\n<p style=\"text-align: justify;\">18. Retinal Vein Occlusion Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Retinal Vein Occlusion treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinal-vein-occlusion-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Retinal Vein Occlusion Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=retinal-vein-occlusion-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-taiwan-liposome-company-aerie-pharmaceuticals-graybug-vision-outlook-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=retinal-vein-occlusion-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-taiwan-liposome-company-aerie-pharmaceuticals-graybug-vision-outlook-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Retinal Vein Occlusion market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Vein Occlusion pipeline products will significantly revolutionize the Retinal Vein Occlusion market dynamics. DelveInsight&rsquo;s &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/retinal-vein-occlusion-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-taiwan-liposome-company-aerie-pharmaceuticals-graybug-vision-outlook-therapeutics_619232.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406],"tags":[],"class_list":["post-619232","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/619232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=619232"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/619232\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=619232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=619232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=619232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}